Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauren D Scherer

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Best Practice & Research. Clinical Haematology|August 23, 2023
Targeted cellular therapy for treatment of relapsed or refractory leukemiaLauren D Scherer, Rayne H Rouce
Frontiers in Oncology|March 21, 2019
Chimeric Antigen Receptors for T-Cell MalignanciesLauren D Scherer, Malcolm K Brenner, Maksim Mamonkin
The Journal of Clinical Investigation|May 5, 2020
Replacing CAR-T cell resistance with persistence by changing a single residueEmily M Hsieh, Lauren D Scherer, Rayne H Rouce
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 10, 2022
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignanciesNorihiro Watanabe, Feiyan Mo, Rong Zheng, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Best Practice & Research. Clinical Haematology|August 23, 2023
Targeted cellular therapy for treatment of relapsed or refractory leukemiaLauren D Scherer, Rayne H Rouce
Frontiers in Oncology|March 21, 2019
Chimeric Antigen Receptors for T-Cell MalignanciesLauren D Scherer, Malcolm K Brenner, Maksim Mamonkin
The Journal of Clinical Investigation|May 5, 2020
Replacing CAR-T cell resistance with persistence by changing a single residueEmily M Hsieh, Lauren D Scherer, Rayne H Rouce
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 10, 2022
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignanciesNorihiro Watanabe, Feiyan Mo, Rong Zheng, et al.
Pageof 1